Mineralys Therapeutics, Inc. (MLYS)
USD 11.64
(-5.75%)
USD 11.64
(-5.75%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -81.17 Million | -29.22 Million | -14.55 Million | -2.46 Million |
| Net Income | -71.89 Million | -29.79 Million | -19.4 Million | -3.42 Million |
| Depreciation & Amortization | - | - | - | - |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | 5.06 Million | 455 Thousand | 80 Thousand | 1000.00 |
| Change in working capital | -7.47 Million | 772 Thousand | 4.08 Million | 480 Thousand |
| Other non-cash items | -6.86 Million | -649 Thousand | 684 Thousand | 482 Thousand |
| Investing Cash Flow | -160.47 Million | -21.75 Million | - | - |
| Investments in PPE | - | - | - | - |
| Acquisitions | - | - | - | - |
| Investment purchases | -347.97 Million | -71.75 Million | - | - |
| Sales/Maturities of investments | 187.5 Million | 50 Million | - | - |
| Other Investing Activities | -160.47 Thousand | -21.75 Thousand | - | - |
| Financing Cash Flow | 203.24 Million | 128.01 Million | 23.81 Million | 3.83 Million |
| Debt repayment | - | - | - | -3.85 Million |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | 64 Thousand | -1.62 Million | - | -20 Thousand |
| Common Stock Issuance | 203.24 Million | 128.01 Million | 23.81 Million | -20 Thousand |
| Other Financing Activities | 203.24 Million | 1.62 Million | 23.81 Thousand | 11.55 Million |
| Accounts receivables | -355 Thousand | - | - | - |
| Accounts payables | 2.41 Million | 3.01 Million | - | - |
| Inventory | - | - | - | - |
| Other working capital | -9.88 Million | 772 Thousand | 4.08 Million | 480 Thousand |
| Cash at beginning of period | 87.7 Million | 10.66 Million | 1.4 Million | 42 Thousand |
| Cash at end of period | 49.3 Million | 87.7 Million | 10.66 Million | 1.4 Million |
| Capital Expenditure | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | -38.39 Million | 77.03 Million | 9.25 Million | 1.36 Million |
| Free Cash Flow | -81.17 Million | -29.22 Million | -14.55 Million | -2.46 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -41.01 Million | -31.5 Million | -71.89 Million | -24.38 Million | -22.76 Million | -12.14 Million |
| Depreciation & Amortization | 9000.00 | 8000.00 | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 2.87 Million | 2.19 Million | 5.06 Million | 1.45 Million | 1.57 Million | 1.27 Million |
| Change in working capital | 10.83 Million | 12.67 Million | -7.47 Million | -3.98 Million | 4.11 Million | -7.53 Million |
| Other non-cash items | 43 Thousand | -302 Thousand | -6.86 Million | -2.06 Million | -1.96 Million | -1.98 Million |
| Investing Cash Flow | 7.73 Million | -55.95 Million | -160.47 Million | -8.08 Million | 4 Million | -16.13 Million |
| Investments in PPE | - | -59 Thousand | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -127.26 Million | -123.39 Million | -347.97 Million | -73.08 Million | -55.99 Million | -56.13 Million |
| Sales/Maturities of investments | 135 Million | 67.5 Million | 187.5 Million | 65 Million | 60 Million | 40 Million |
| Other Investing Activities | 7736.00 | -55.89 Thousand | -160.47 Thousand | -8089.00 | 4007.00 | -16.13 Thousand |
| Financing Cash Flow | -152 Thousand | 116.2 Million | 203.24 Million | 74 Thousand | 184 Thousand | -581 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | 64 Thousand | 64.58 Thousand | - | -581.00 |
| Common Stock Issuance | -152 Thousand | 116.2 Million | 203.24 Million | 74 Thousand | 184 Thousand | -581 Thousand |
| Other Financing Activities | -284 Thousand | -63 Thousand | 203.24 Million | 74.00 | 184.00 | - |
| Accounts receivables | 184 Thousand | - | - | - | - | - |
| Accounts payables | - | 8.4 Million | 2.41 Million | 503 Thousand | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 10.83 Million | 12.67 Million | -9.88 Million | -3.98 Million | 4.11 Million | -7.53 Million |
| Cash at beginning of period | 90.41 Million | 49.3 Million | 87.7 Million | 86.3 Million | 101.14 Million | 138.24 Million |
| Cash at end of period | 67.85 Million | 90.41 Million | 49.3 Million | 49.3 Million | 86.3 Million | 101.14 Million |
| Capital Expenditure | - | -59 Thousand | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -22.56 Million | 41.11 Million | -38.39 Million | -36.99 Million | -14.84 Million | -37.1 Million |
| Free Cash Flow | -30.14 Million | -19.19 Million | -81.17 Million | -28.98 Million | -19.03 Million | -20.38 Million |
IPAR
601686
SPC
MOGLF
ADVOF
0017